Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hutchmed China Ltd ADR
(NQ:
HCM
)
18.41
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
18.41
Bid (Size)
18.50 (20)
Ask (Size)
19.50 (3)
Prev. Close
18.41
Today's Range
18.41 - 18.41
52wk Range
10.68 - 20.73
Shares Outstanding
871,256,270
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
April 05, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Performance
YTD
+5.14%
+5.14%
1 Month
+9.52%
+9.52%
3 Month
+35.87%
+35.87%
6 Month
+4.90%
+4.90%
1 Year
+26.36%
+26.36%
More News
Read More
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
April 02, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
March 27, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 14, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 13, 2024
Via
Benzinga
Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
March 13, 2024
Via
Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 13, 2024
Via
InvestorPlace
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
Via
Benzinga
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
February 28, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
February 14, 2024
Via
Benzinga
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
February 06, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
February 03, 2024
Via
Talk Markets
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
February 02, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2023 Final Results
February 01, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
January 29, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
January 10, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
December 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
November 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
November 24, 2023
Via
Benzinga
Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know
November 10, 2023
Via
Benzinga
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
November 10, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
November 08, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
November 08, 2023
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.